TGF-β favors bone marrow-derived dendritic cells to acquire tolerogenic properties. (May 2014)

• Record Type: Journal Article
• Authors: Song, Sha-Sha; Yuan, Ping-Fan; Chen, Jing-Yu; Fu, Jing-Jing; Wu, Hua-Xun; Lu, J. T.; Wei, W.
• Is Part Of: Immunological investigations. Volume 43:Number 4(2014)
• Page Start: 360
• Page End: 369
• Publication Date: 2014-05
• Subjects: Immunology -- Periodicals; Immunochemistry -- Periodicals; Cellular immunity -- Periodicals; Communicable diseases -- Periodicals; 616.079
• DOI: 10.3109/08820139.2013.879172
• Languages: English
• ISSNs: 0882-0139

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Dendritic cells (DCs) are the most powerful antigen-presenting cells that have an important role in the immunity and immune tolerance. Transforming growth factor β (TGF-β) is a pleiotropic cytokine widely expressing in various tissues and cells, which regulates cellular proliferation, differentiation and apoptosis of several immune cells and is considered to be a key factor in inducing immune tolerance. The effect of TGF-β on DCs is very complex. In this study, we further investigated the effect of TGF-β on inducing immune tolerance of DCs. DCs were differentiated from mice bone marrow cells in the absence or presence of TGF-β. The phenotype as well as function was studied in detail. We found that TGF-β limited the expression of CD40, CD83, CD86 and MHCII in DCs, increased CD45RB and indoleamine 2, 3-dioxygenase (IDO) expression in DCs, promoted IL-10 and limited IL-12 secretion by DCs. Moreover, TGF-β increased the endocytosis ability of DCs and limited the ability of DCs in activating T cells. These results suggest that TGF-β affects the immunity of DCs and enhances their tolerogenicity.</p> </abstract>